$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Gulf Island Fabrication, Inc. (NASDAQ: GIFI)

(NASDAQ:GIFI), NEW YORK, Nov. 11, 2025 (GLOBE NEWSWIRE) — Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire […]

Stingray Reports Second Quarter Results for Fiscal 2026

Stingray Reports Second Quarter Results for Fiscal 2026 Transformative TuneIn acquisition and strategic DMI deal to accelerate top growth vectors GlobeNewswire November 11, 2025 Organic growth increased 16.7% year-over-year in Broadcast and Recurring Commercial Music Revenues; Revenues grew 21.0% to $113.3 million in the second quarter of 2026 from $93.6 million in the second quarter

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Gulf Island Fabrication, Inc. (NASDAQ: GIFI)

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Gulf Island Fabrication, Inc. (NASDAQ: GIFI) GlobeNewswire November 11, 2025 NEW YORK, Nov. 11, 2025 (GLOBE NEWSWIRE) — Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as

Integrated Rail and Resources Acquisition Corp. Announces Extension

Integrated Rail and Resources Acquisition Corp. Announces Extension GlobeNewswire November 11, 2025 WINTER PARK, Fla., Nov. 11, 2025 (GLOBE NEWSWIRE) — Pursuant to the Investment Management Trust Agreement between Integrated Rail and Resources Acquisition Corp. (the “Company”) and American Stock Transfer & Trust Company, LLC, dated as of November 11, 2021, as amended on February

Stingray Acquires TuneIn, Creating an Audio Streaming and Advertising Powerhouse

Stingray Acquires TuneIn, Creating an Audio Streaming and Advertising Powerhouse GlobeNewswire November 11, 2025 Transaction enterprise value of up to US$175 million US$150 million paid out at closing, and up to US$25 million paid one-year post-closing TuneIn expected to achieve US$110 million of revenues and US$30 million of adjusted EBITDA1 for the twelve-month period ending

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Northern Data AG (OTCMKTS: NDTAF)

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Northern Data AG (OTCMKTS: NDTAF) GlobeNewswire November 11, 2025 NEW YORK, Nov. 11, 2025 (GLOBE NEWSWIRE) — Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a

Eledon Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

(NASDAQ:ELDN), IRVINE, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares and pre-funded

Eledon Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Eledon Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants GlobeNewswire November 11, 2025 IRVINE, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain

CureGene Unveils Groundbreaking Preclinical Data for CG-0416, a Novel Oral Non-GLP-1 Therapy, at Obesity Week 2025

CG-0416, a highly liver-targeted THR-B agonist, demonstrates high-quality weight loss by reducing fat mass while preserving muscle, both as a monotherapy and in combination with GLP-1 RAs. CureGene Pharmaceuticals (“CureGene”) today announced the first disclosure of groundbreaking preclinical data for CG-0416, a novel oral non-GLP-1 weight-loss agent, in the Late-Breaking poster session (Poster-350) at Obesity

Upexi Reports Record Digital Asset Revenue for Fiscal First Quarter 2026

(NASDAQ:UPXI), Digital Asset Revenue was Approximately $6.1 Million for the Quarter Gross Profit Totaled $8.3 Million, up 183% Year-Over-Year Net Income Increased to $66.7 Million, Compared to a Net Loss of $1.6 Million, Year-over-Year Conference Call Scheduled for today, November 11, 2025, at 5:30 p.m. Eastern Time TAMPA, Fla., Nov. 11, 2025 (GLOBE NEWSWIRE) —

Scroll to Top